UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 333-191725

 

REGEN BIOPHARMA, INC

 

(Exact name of registrant as specified in its charter)

 

4700 Spring Street, St 304, La Mesa, California 91942

(619) 722 5505

 

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock

Series A Preferred Stock

 

(Title of each class of securities covered by this Form)

None

 

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  Rule 12g-4(a)(1) ☐
     
  Rule 12g-4(a)(2) ☐
     
  Rule 12h-3(b)(1)(i) ☐
     
  Rule 12h-3(b)(1)(ii) ☒
     
  Rule 15d-6 ☐

 

Approximate number of holders of record as of the certification or notice date:

 

Common Stock: 482

 

Series A Preferred Stock 480

 

Pursuant to the requirements of the Securities Exchange Act of 1934 Regen Biopharma, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date:     By: /s/ David R Koos
        David R Koos
Chairman, CEO, CFO, President, Secretary Officer, Treasurer

 

 

 

 

Regen Biopharma (PK) (USOTC:RGBPP)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas Regen Biopharma (PK).
Regen Biopharma (PK) (USOTC:RGBPP)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas Regen Biopharma (PK).